Prognosis of Behcet's syndrome among men with mucocutaneous involvement at disease onset: long-term outcome of patients enrolled in a controlled trial

Basit Öğe Kaydı
dc.authoridTascilar, Koray/0000-0002-8109-826X
dc.authoridHamuryudan, Vedat/0000-0001-6625-1652
dc.authoridHatemi, Gulen/0000-0002-1952-1135;
dc.authorwosidTascilar, Koray/F-9070-2015
dc.authorwosidYURDAKUL, SEBAHATTİN/AAY-1069-2020
dc.authorwosidSEYAHI, EMIRE/AAB-3576-2020
dc.authorwosidHamuryudan, Vedat/AAA-1100-2020
dc.authorwosidHatemi, Gulen/AAC-9647-2021
dc.authorwosidHatemi, Gulen/AFM-7014-2022
dc.authorwosidSeyahi, Emire/AAD-1769-2021
dc.contributor.authorHamuryudan, Vedat
dc.contributor.authorHatemi, Gulen
dc.contributor.authorTascilar, Koray
dc.contributor.authorSut, Necdet
dc.contributor.authorOzyazgan, Yilmaz
dc.contributor.authorSeyahi, Emire
dc.contributor.authorMat, Cem
dc.date.accessioned2024-06-12T10:54:21Z
dc.date.available2024-06-12T10:54:21Z
dc.date.issued2010
dc.departmentTrakya Üniversitesien_US
dc.description.abstractObjective. To assess the influence of being free of major organ involvement during the early years of the disease on the prognosis of men with Behcet's syndrome (BS). Methods. Ninety-six men with BS, who had only active mucocutaneous manifestations when entering a controlled trial of thalidomide mean (S. D.) 11.7 (0.8) years ago, were re-evaluated for the use of immunosuppressives as an indication of major organ involvement during the post-trial period. Results. Outcome information was obtained in 91 (95%) patients. Thirty-nine (43%) patients had to use immunosuppressives during the post-trial period. Immunosuppressive use was significantly more frequent among patients developing BS at younger age (76%; 424 years) than older age (30%; 525 years). Developing BS at young age (OR 6.3; 95% CI 2.09, 19.04) and not using colchicine during the post-trial period (OR = 3.860; 95% CI 1.484, 10.034) were risk factors for immunosuppressive use. However, 82% of the patients using colchicine had onset during old age. Colchicine showed a significant effect in decreasing the use of immunosuppressives only among patients of old age at onset (Fisher's exact test = 5.026; P = 0.031) in the subgroup analysis. Eye disease (18 patients) and vascular involvement (14 patients) were the most frequent indications for immunosuppressive use. Conclusions. Being free of major organ involvement during the early years of BS does not indicate a mild prognosis for men developing BS at young age. Whether colchicine will reduce the need for immunosuppressive use among men developing BS at old age awaits formal studies.en_US
dc.identifier.doi10.1093/rheumatology/kep350
dc.identifier.endpage177en_US
dc.identifier.issn1462-0324
dc.identifier.issue1en_US
dc.identifier.pmid19995858en_US
dc.identifier.startpage173en_US
dc.identifier.urihttps://doi.org/10.1093/rheumatology/kep350
dc.identifier.urihttps://hdl.handle.net/20.500.14551/19017
dc.identifier.volume49en_US
dc.identifier.wosWOS:000273699000025en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherOxford Univ Pressen_US
dc.relation.ispartofRheumatologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBehcet's Syndromeen_US
dc.subjectPrognosisen_US
dc.subjectMortalityen_US
dc.subjectThalidomideen_US
dc.subjectYoungen_US
dc.subjectCohort Studyen_US
dc.subjectUveitisen_US
dc.subjectDouble-Blind Trialen_US
dc.subjectColchicineen_US
dc.subjectMortalityen_US
dc.subjectUveitisen_US
dc.titlePrognosis of Behcet's syndrome among men with mucocutaneous involvement at disease onset: long-term outcome of patients enrolled in a controlled trialen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu